BARINTHUS BIOTHERAPEUTICS PL
BRNSNASDAQTrading Snapshot
- Day Range
- $0.66 β $0.76
- 52-Week Range
- $0.51 β $0.85
- Volume (shares)
- 376,145
- Avg Volume (shares)
- β
- Shares Outstanding
- 40.9M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-1.64
- Dividend Yield
- β
- Dilution (1yr)
- +3.0%
BARINTHUS BIOTHERAPEUTICS PL
BRNSAbout BARINTHUS BIOTHERAPEUTICS PL
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.